Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
Thiago Cerqueira‐Silva, Jason R. Andrews, Viviane Boaventura, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 6, pp. 791-801
Open Access | Times Cited: 120

Showing 26-50 of 120 citing articles:

Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia
Júlia Spinardi, Ana Carolina Dantas, Carolina Carballo, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1237-1264
Open Access | Times Cited: 12
Real-World Effectiveness of Four Types of COVID-19 Vaccines
Derar H. Abdel‐Qader, Hasan Abdel-Qader, Jennifer Silverthorne, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 985-985
Open Access | Times Cited: 12
Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis
Martin Law, Sam S.H. Ho, Gigi Kwan Chi Tsang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 37, pp. 100788-100788
Open Access | Times Cited: 12
Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel
Jacob Waxman, Maya Makov-Assif, Ben Y. Reis, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
Lia Reynolds, Cate Dewey, Ghaid Asfour, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 11
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
Nungruthai Suntronwong, Sitthichai Kanokudom, Chompoonut Auphimai, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 180-180
Open Access | Times Cited: 3
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Sue Ann Costa Clemens, Brett Jepson, Qasim Bhorat, et al.
The Lancet Microbe (2024), pp. 100863-100863
Open Access | Times Cited: 3
Profile of COVID-19 in Brazil—risk factors and socioeconomic vulnerability associated with disease outcome: retrospective analysis of population-based registers
Felipe Augusto Pereira, Fábio M H S Filho, Arthur R. de Azevedo, et al.
BMJ Global Health (2022) Vol. 7, Iss. 12, pp. e009489-e009489
Open Access | Times Cited: 17
BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐CoV‐2 Infection Among Patients With Cardiovascular Disease
Xuxiao Ye, Vincent Ka Chun Yan, Hei Hang Edmund Yiu, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 9
Open Access | Times Cited: 9
An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants
Zongming Liu, Jiaxuan Li, Shanshan Pei, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 9
Targeting SARS-CoV-2 and host cell receptor interactions
Siew Pheng Lim
Antiviral Research (2022) Vol. 210, pp. 105514-105514
Open Access | Times Cited: 15
Effectiveness of COVID-19 Vaccination on Reduction of Hospitalizations and Deaths in Elderly Patients in Rio Grande do Norte, Brazil
Ana Isabela L. Sales-Moioli, Leonardo J. Galvão-Lima, Talita K. B. Pinto, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 21, pp. 13902-13902
Open Access | Times Cited: 14
Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 14
Far-right political ideology and COVID-19 vaccine hesitancy: Multilevel analysis of 21 European countries
Insa Backhaus, Hanno Hoven, Ichiro Kawachi
Social Science & Medicine (2023) Vol. 335, pp. 116227-116227
Closed Access | Times Cited: 8
How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
Juan Carlos Alzate-Ángel, Paula A. Avilés-Vergara, David Arango-Londoño, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020–2023
Emil Kupek
Vaccine (2024) Vol. 42, Iss. 15, pp. 3437-3444
Closed Access | Times Cited: 2
Estimated deaths averted in adults by COVID-19 vaccination in select Latin American and Caribbean Countries
Alexandra Savinkina, Daniel M. Weinberger, Cristiana M. Toscano, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 10
Open Access | Times Cited: 2
Effectiveness of the first and second SARS-CoV-2 vaccine dose: a nationwide cohort study from Austria on hybrid versus natural immunity
Alena Chalupka, Uwe Riedmann, Lukáš Richter, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 10
Open Access | Times Cited: 2
COVID vaccine plus infection can lead to months of immunity
Saima Sidik
Nature (2022)
Closed Access | Times Cited: 13
Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study
Eric Yuk Fai Wan, Anna Hoi Ying Mok, Vincent Ka Chun Yan, et al.
Journal of Travel Medicine (2022) Vol. 29, Iss. 8
Open Access | Times Cited: 13
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Margaret L. Lind, Alexander J. Robertson, Julio Silva, et al.
PLoS Medicine (2022) Vol. 19, Iss. 12, pp. e1004136-e1004136
Open Access | Times Cited: 12
Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study
Simon Xiwen Qin, Franco Wing Tak Cheng, Wang Chun Kwok, et al.
Drug Safety (2023) Vol. 47, Iss. 2, pp. 135-146
Open Access | Times Cited: 7
Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India
Sandeep Budhiraja, Abhaya Indrayan, Monica Mahajan
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection after Booster Dose of mRNA COVID-19 Vaccine: The MOSAICO Study
Pietro Ferrara, D. Ponticelli, Roberto Magliuolo, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1353-1353
Open Access | Times Cited: 11
Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study
Higor S. Monteiro, Antonio S. Lima Neto, Rebecca Kahn, et al.
Vaccine (2023) Vol. 41, Iss. 39, pp. 5742-5751
Open Access | Times Cited: 6

Scroll to top